Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Amortization - Intangibles (2016 - 2025)

Historic Amortization - Intangibles for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $1.8 million.

  • Vanda Pharmaceuticals' Amortization - Intangibles changed 0.0% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 884.19%. This contributed to the annual value of $7.3 million for FY2024, which is 24799.04% up from last year.
  • Vanda Pharmaceuticals' Amortization - Intangibles amounted to $1.8 million in Q3 2025, which was down 0.0% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Amortization - Intangibles registered a high of $2.0 million during Q1 2024, and its lowest value of $369000.0 during Q4 2021.
  • Over the past 5 years, Vanda Pharmaceuticals' median Amortization - Intangibles value was $400000.0 (recorded in 2021), while the average stood at $951105.3.
  • Its Amortization - Intangibles has fluctuated over the past 5 years, first skyrocketed by 40450.0% in 2024, then plummeted by 1080.28% in 2025.
  • Vanda Pharmaceuticals' Amortization - Intangibles (Quarter) stood at $369000.0 in 2021, then grew by 2.71% to $379000.0 in 2022, then skyrocketed by 151.45% to $953000.0 in 2023, then surged by 83.84% to $1.8 million in 2024, then grew by 2.74% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $1.8 million for Q2 2025, and $1.8 million during Q1 2025.